[go: up one dir, main page]

WO2009067520A3 - Peptides specific for hepatocellular carcinoma cells and applications thereof - Google Patents

Peptides specific for hepatocellular carcinoma cells and applications thereof Download PDF

Info

Publication number
WO2009067520A3
WO2009067520A3 PCT/US2008/084043 US2008084043W WO2009067520A3 WO 2009067520 A3 WO2009067520 A3 WO 2009067520A3 US 2008084043 W US2008084043 W US 2008084043W WO 2009067520 A3 WO2009067520 A3 WO 2009067520A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcc
tumor
hepatocellular carcinoma
tumor tissues
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/084043
Other languages
French (fr)
Other versions
WO2009067520A2 (en
Inventor
Han-Chung Wu
Chin-Tarng Lin
Albert Lo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Priority to JP2010534284A priority Critical patent/JP2011504361A/en
Priority to EP08851894.9A priority patent/EP2225262B1/en
Priority to CN2008801247432A priority patent/CN101918433B/en
Publication of WO2009067520A2 publication Critical patent/WO2009067520A2/en
Publication of WO2009067520A3 publication Critical patent/WO2009067520A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31). With the conjugation of SP94 and liposomal doxorubicin, a targeted drug delivery system enhanced the therapeutic efficacy against HCC xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that SP94 can improve the systemic treatment of patients with advanced HCC.
PCT/US2008/084043 2007-11-20 2008-11-19 Peptides specific for hepatocellular carcinoma cells and applications thereof Ceased WO2009067520A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2010534284A JP2011504361A (en) 2007-11-20 2008-11-19 Peptides specific for hepatocellular carcinoma cells and their applications
EP08851894.9A EP2225262B1 (en) 2007-11-20 2008-11-19 Peptides specific for hepatocellular carcinoma cells and applications thereof
CN2008801247432A CN101918433B (en) 2007-11-20 2008-11-19 Peptides specific to hepatocellular carcinoma cells and their applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99648807P 2007-11-20 2007-11-20
US60/996,488 2007-11-20

Publications (2)

Publication Number Publication Date
WO2009067520A2 WO2009067520A2 (en) 2009-05-28
WO2009067520A3 true WO2009067520A3 (en) 2009-09-03

Family

ID=40329430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/084043 Ceased WO2009067520A2 (en) 2007-11-20 2008-11-19 Peptides specific for hepatocellular carcinoma cells and applications thereof

Country Status (6)

Country Link
US (1) US8541543B2 (en)
EP (1) EP2225262B1 (en)
JP (1) JP2011504361A (en)
CN (1) CN101918433B (en)
TW (1) TWI372866B (en)
WO (1) WO2009067520A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102732522A (en) * 2012-02-27 2012-10-17 南昌大学 Liver cancer serum nucleic acid aptamers

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138550A1 (en) * 2009-05-27 2010-12-02 Northeastern University Conjugated nanodelivery vehicles
EP4116331A1 (en) * 2012-12-17 2023-01-11 PF Argentum IP Holdings LLC Treatment of cd47+ disease cells with sirp alpha-fc fusions
CN103804473B (en) * 2014-01-23 2016-01-20 浙江大学 One peptide species and comprise the nucleic acid drug nanoparticle of this polypeptide
CN103804472B (en) * 2014-01-23 2016-06-08 浙江大学 A kind of taxone precursor
CN104667290A (en) * 2014-10-25 2015-06-03 中国科学技术大学 Targeting peptide-modified gold nanoparticle and preparation method thereof as well as application of targeting peptide-modified gold nanoparticle as platinic pro-drug carrier
CN105039333B (en) * 2015-08-21 2018-07-24 天津医科大学 Hepatoma-targeting peptide and its application

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) * 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) * 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6663885B1 (en) * 1993-03-15 2003-12-16 A. Natterman & Cie Gmbh Aqueous liposome system and a method for the preparation of such a liposome system
ES2115343T3 (en) * 1993-11-05 1998-06-16 Amgen Inc METHOD OF PREPARATION OF LIPOSOMES AND ENCAPSULATION OF MATERIAL.
US6051251A (en) * 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
AU2001238179A1 (en) * 2000-02-10 2001-08-20 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
CA2489186C (en) * 2002-06-07 2013-01-15 Wisconsin Alumni Research Foundation Chemical synthesis of reagents for peptide coupling
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
US7501486B2 (en) * 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALLEN T M: "Ligand-targeted therapeutics in anticancer therapy", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 2, no. 10, 1 October 2002 (2002-10-01), pages 750 - 763, XP002465379, ISSN: 1474-175X *
DU ET AL: "In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 342, no. 3, 14 April 2006 (2006-04-14), pages 956 - 962, XP005312610, ISSN: 0006-291X *
HALM U ET AL: "A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JAN 2000, vol. 11, no. 1, January 2000 (2000-01-01), pages 113 - 114, XP002516889, ISSN: 0923-7534 *
HAN CLIFF S ET AL: "Pathogenomic sequence analysis of Bacillus cereus and Bacillus thuringiensis isolates closely related to Bacillus anthracis", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 188, no. 9, 1 May 2006 (2006-05-01), pages 3382 - 3390, XP002451173, ISSN: 0021-9193 *
LAUREN R H KRUMPE ET AL: "The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS ; FORMERLY KNOWN AS LETTERS IN PEPTIDE SCIENCE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 12, no. 1, 1 March 2006 (2006-03-01), pages 79 - 91, XP019256882, ISSN: 1573-3904 *
PASTORINO FABIO ET AL: "Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 66, no. 20, 1 October 2006 (2006-10-01), pages 10073 - 10082, XP002488419, ISSN: 0008-5472 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102732522A (en) * 2012-02-27 2012-10-17 南昌大学 Liver cancer serum nucleic acid aptamers
CN102732522B (en) * 2012-02-27 2014-04-09 南昌大学 Liver cancer serum nucleic acid aptamers

Also Published As

Publication number Publication date
US20090136418A1 (en) 2009-05-28
WO2009067520A2 (en) 2009-05-28
EP2225262A2 (en) 2010-09-08
CN101918433B (en) 2013-06-26
JP2011504361A (en) 2011-02-10
TWI372866B (en) 2012-09-21
EP2225262B1 (en) 2016-04-27
US8541543B2 (en) 2013-09-24
TW200935055A (en) 2009-08-16
CN101918433A (en) 2010-12-15

Similar Documents

Publication Publication Date Title
WO2009067520A3 (en) Peptides specific for hepatocellular carcinoma cells and applications thereof
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
WO2002002147A3 (en) Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
Hilchie et al. Enhanced killing of breast cancer cells by a d-amino acid analog of the winter flounder-derived pleurocidin NRC-03
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
WO2008031016A3 (en) Heterocyclic ligands for integrin imaging and therapy
WO2008100481A3 (en) Lung cancer-targeted peptides and applications thereof
WO2008100482A3 (en) Peptides that target to tumor blood vessels of lung cancer and applications thereof
JP6462147B2 (en) HSP90 inhibitory peptide conjugate and its application in tumor therapy
JP7658627B2 (en) Accumulative boron-10 agents capable of rapid, selective and localized targeting of tumor tissue for boron neutron capture therapy
Broughton et al. Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy
CN113993554A (en) Targeting compounds for cancers selected from esophagus, throat, lung, brain and intestine
Grosmanová et al. Novel strategies for enhanced fluorescence visualization of glioblastoma tumors based on HPMA copolymers conjugated with tumor targeting and/or cell‐penetrating peptides
CN102127154A (en) A54-GFLG-DOX conjugate as well as coupling method and application thereof
Ming et al. Therapeutic effect of oridonin on mice with prostate cancer
Schrump et al. Novel molecular targeted therapy for esophageal cancer
JP2014523437A (en) Novel zinc finger-like peptide compositions as potent drugs in cancer prevention and treatment
AU2021267196A1 (en) Anti-cancer proteins
Pathuri et al. Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor
WO2005113720A3 (en) A strategy for designing patient-specific anti-cancer drugs
RU2010140888A (en) IMPROVED ANTI-CANCER THERAPIES
Sivalingam et al. Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy
Jin et al. A tumor-specific tissue-penetrating peptide enhances the efficacy of chemotherapy drugs in gastric cancer
TW200833355A (en) Peptides that target to tumor blood vessels of lung cancer and applications thereof
WO2018183232A3 (en) Peptides and methods for targeted delivery to tumors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880124743.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08851894

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010534284

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008851894

Country of ref document: EP